Lead Product(s): CT-868
Therapeutic Area: Endocrinology Product Name: CT-868
Highest Development Status: Phase I Product Type: Peptide
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: $47.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing September 30, 2020
The funding will support initiation early in 2021 of a 26-week dose ranging phase 2 study for CT-868 and phase 1-2 studies for CT-388 and involve more than 300 patients.